Liver mass primary prevention
|
Liver Mass Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Liver mass primary prevention On the Web |
|
American Roentgen Ray Society Images of Liver mass primary prevention |
|
Risk calculators and risk factors for Liver mass primary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] ; Associate Editor(s)-in-Chief: Aditya Ganti M.B.B.S. [2]
Overview
Effective measures for the primary prevention of liver lesions include limited use of OCP's, vaccination for hepatitis, alcohol cessation, especially in cirrhotic patients, avoidance of hepatotoxic drugs, physical exercise, smoking cessation, adequate caloric intake, prevention of obesity, screening of blood donors for Hepatitis B, Hepatitis C.
Primary Prevention
Effective measures for the primary prevention of liver lesions include:[1][2][3][4][5][6][7][8][9]
- Limited use of OCP's
- Vaccination for Hepatitis B
- Alcohol cessation, especially in cirrhotic patients
- Avoidance of hepatotoxic drugs
- Physical exercise
- Smoking cessation
- Adequate caloric intake
- Prevention of obesity
- Screening of blood donors for Hepatitis B, Hepatitis C
References
- ↑ Chang MH, You SL, Chen CJ, Liu CJ, Lee CM, Lin SM, Chu HC, Wu TC, Yang SS, Kuo HS, Chen DS (2009). "Decreased incidence of hepatocellular carcinoma in hepatitis B vaccinees: a 20-year follow-up study". J. Natl. Cancer Inst. 101 (19): 1348–55. doi:10.1093/jnci/djp288. PMID 19759364.
- ↑ Wiegand J, Berg T (2013). "The etiology, diagnosis and prevention of liver cirrhosis: part 1 of a series on liver cirrhosis". Dtsch Arztebl Int. 110 (6): 85–91. doi:10.3238/arztebl.2013.0085. PMC 3583179. PMID 23451000.
- ↑ "2014 Korean Liver Cancer Study Group-National Cancer Center Korea practice guideline for the management of hepatocellular carcinoma". Korean J Radiol. 16 (3): 465–522. 2015. doi:10.3348/kjr.2015.16.3.465. PMC 4435981. PMID 25995680.
- ↑ Kuffner EK, Dart RC, Bogdan GM, Hill RE, Casper E, Darton L (2001). "Effect of maximal daily doses of acetaminophen on the liver of alcoholic patients: a randomized, double-blind, placebo-controlled trial". Arch. Intern. Med. 161 (18): 2247–52. PMID 11575982.
- ↑ Mazoit JX, Sandouk P, Zetlaoui P, Scherrmann JM (1987). "Pharmacokinetics of unchanged morphine in normal and cirrhotic subjects". Anesth. Analg. 66 (4): 293–8. PMID 3565791.
- ↑ Wörns MA, Teufel A, Kanzler S, Shrestha A, Victor A, Otto G, Lohse AW, Galle PR, Höhler T (2008). "Incidence of HAV and HBV infections and vaccination rates in patients with autoimmune liver diseases". Am. J. Gastroenterol. 103 (1): 138–46. doi:10.1111/j.1572-0241.2007.01609.x. PMID 17970833.
- ↑ Chu CM, Liaw YF (2005). "Increased incidence of fulminant hepatic failure in previously unrecognized HBsAg carriers with acute hepatitis independent of etiology". Infection. 33 (3): 136–9. doi:10.1007/s15010-005-4094-4. PMID 15940414.
- ↑ Eckman MH, Kaiser TE, Sherman KE (2011). "The cost-effectiveness of screening for chronic hepatitis B infection in the United States". Clin. Infect. Dis. 52 (11): 1294–306. doi:10.1093/cid/cir199. PMC 3097367. PMID 21540206.
- ↑ Bellentani S, Saccoccio G, Costa G, Tiribelli C, Manenti F, Sodde M, Saveria Crocè L, Sasso F, Pozzato G, Cristianini G, Brandi G (1997). "Drinking habits as cofactors of risk for alcohol induced liver damage. The Dionysos Study Group". Gut. 41 (6): 845–50. PMC 1891602. PMID 9462221.